Sign Up
Stories
Breakthrough in Allergic Asthma Treatment
Share
Advancements in Cancer Treatment and Mar...
Biosimilar Partnership in U.S.
Dupixent's Priority Review for EoE Treat...
AI-Powered Cancer Drug Trials
ANJESO Drug Insight and Market Forecast
Acne Relief: Stiftung Warentest's Top Pi...
Overview
API
Stallergenes Greer's EfficAPSI study, published in Lancet Regional Health-Europe, reveals the significant benefits of its liquid sublingual allergen immunotherapy (AIT) on allergic asthma in over 440,000 patients in France. The study underscores a reduced risk of asthma events with SLIT-liquid, emphasizing its impact on asthma management.
Ask a question
How might the findings of this study influence the development of future treatments for allergic asthma?
In what ways could this research impact the perception and utilization of allergen immunotherapy in clinical practice?
What challenges could arise in implementing liquid sublingual allergen immunotherapy on a broader scale?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Feb 2024
Mar 2024
Apr 2024
Coverage